Skip to main content

Table 15 The cost-effectiveness analysis in the 24-month period (the incidence of normal blood glucose)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group

C (yuan)

E (%)

C/E

ΔC/ΔE

The treatment group

41367830.8

20.3

2037824.8

−307040.6

The control group

37529823.2

32.8

1144201.0

 
  1. C the total costs, C/E the cost-effectiveness ratio, ΔC/ΔE the incremental cost-effectiveness ratio
Back to article page

Trials

ISSN: 1745-6215